We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
InMed Pharmaceuticals and the Almac Group have partnered on a proprietary approach to augment current biosynthesis-based methods for cannabinoid production.
Almac Group, the global contract development and manufacturing organisation, is delighted to announce the successful MHRA registration of its High Throughput GMP Peptide manufacturing facility.